Figure 6.

Luciferase Expression and Biodistribution in Mice

Mice were tail-vein injected with AAV9 containing luciferase produced from Sf9, ExpiSf9, or Ad293 cells. (A) The mice were imaged by the In Vivo Imaging System (IVIS) at day 14, with the Sf9-derived AAV9 group (top), ExpiSf9-derived AAV9 group (middle), and Ad293-derived group (bottom). (B) In vivo luciferase signals were quantitated, and the average total flux (photons per second [p/s]) for each group of five mice is shown. ∗∗p < 0.005 and ∗∗∗p < 0.0005. (C) Ex vivo images of the mice organs were also taken at day 21, with the Sf9-derived AAV9 group (top), ExpiSf9-derived AAV9 group (middle), and Ad293-derived AAV9 group (bottom). (D) Ex vivo luciferase signals were quantitated, and the average total flux (p/s) for each group of two mice is shown (upper panel). qPCR was performed on DNA extracted from the collected mice tissues to quantitate how many copies of AAV viral genomes were present (lower panel). Sf9-derived AAV9 (green), ExpiSf9-derived AAV9 (yellow), and Ad293-derived AAV9 (blue). ∗p < 0.05, comparing Sf9-derived AAV9 to ExpiSf9-derived AAV9; &p < 0.05, comparing ExpiSf9-derived AAV9 to Ad293-derived AAV9; #p < 0.05, comparing Sf9-derived AAV9 to Ad293-derived AAV9.